PTC Therapeutics (NASDAQ:PTCT) Announces Quarterly Earnings Results

PTC Therapeutics (NASDAQ:PTCT) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.76), FiscalAI reports. The firm had revenue of $357.81 million for the quarter, compared to analysts’ expectations of $306.43 million. PTC Therapeutics’s quarterly revenue was up 69.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.20 EPS.

Here are the key takeaways from PTC Therapeutics’ conference call:

• Guidance was raised after a record quarter: Third-quarter total revenue reached $358 million, including $276 million in product revenue, and 2026 product revenue guidance increased to $960 million–$990 million. Management also reiterated its expectation to reach cash-flow breakeven this year.
• SEPHIENCE launch momentum remains strong: Global SEPHIENCE revenue was $182 million, up more than 20% sequentially, with over 2,000 active patients worldwide and strong adherence. PTC said the U.S. launch is entering a durable growth phase and maintained its confidence in a $2 billion-plus peak-sales opportunity.
• ST-920 adds a potentially near-term growth driver: PTC expects to complete its rolling BLA submission for the Fabry gene therapy in the fourth quarter, with potential approval and launch in 2027. The company said the $111 million acquisition could be accretive in 2027 and noted ST-920’s RMAT designation may support priority review.
• Mature DMD products face increasing pressure: A new Emflaza generic entrant has significantly reduced pricing, while Translarna’s third-quarter revenue benefited from an unexpected Russian government order that PTC does not expect to repeat in the fourth quarter.
• Votoplam’s regulatory discussion was delayed: The FDA Type C meeting on the Huntington’s disease program is now expected in the first quarter of 2027 rather than late 2026, although global enrollment in the 770-patient INVEST-HD Phase III study continues.

PTC Therapeutics Trading Down 7.0%

Shares of NASDAQ:PTCT traded down $4.49 during trading on Friday, reaching $59.97. The company had a trading volume of 2,357,501 shares, compared to its average volume of 1,013,192. The company has a fifty day moving average of $65.36 and a two-hundred day moving average of $70.78. The stock has a market capitalization of $5.01 billion, a P/E ratio of -42.84, a price-to-earnings-growth ratio of 1.95 and a beta of 0.49. PTC Therapeutics has a 12 month low of $58.80 and a 12 month high of $90.87.

Insider Activity

In related news, VP Mark Boulding sold 435 shares of the company’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $64.16, for a total value of $27,909.60. Following the completion of the transaction, the vice president directly owned 105,272 shares in the company, valued at approximately $6,754,251.52. The trade was a 0.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Glenn Md Phd Steele, Jr. sold 12,000 shares of the stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $65.16, for a total value of $781,920.00. Following the completion of the transaction, the director directly owned 22,500 shares in the company, valued at approximately $1,466,100. This represents a 34.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 77,370 shares of company stock worth $5,322,261. 5.30% of the stock is currently owned by corporate insiders.

Key PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Raised 2026 outlook and strong revenue growth: PTC reported third-quarter revenue of approximately $358 million, up 69.6% year over year, including $276 million in product revenue. Management increased full-year 2026 revenue guidance to $1.29 billion-$1.32 billion and product revenue guidance to $960 million-$990 million. Sephience revenue reached $182 million, supported by U.S. growth and international expansion. PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Analysts raised price targets: TD Cowen lifted its target from $90 to $95 and maintained a “buy” rating. Wells Fargo raised its target from $109 to $112 and kept an “overweight” rating, signaling substantial potential upside based on the current valuation. TD Cowen recommendations Wells Fargo price target update
• Positive Sentiment: Pipeline expansion: PTC acquired ST-920, a Fabry disease gene therapy, and expects to complete its biologics license application submission in the fourth quarter, adding a potential future growth catalyst. PTC corporate update
• Neutral Sentiment: Royal Bank of Canada raised its price target from $75 to $77 but retained a “sector perform” rating, indicating improved valuation expectations without a bullish change in its recommendation. RBC recommendations
• Negative Sentiment: Quarterly loss weighed on sentiment: PTC reported a GAAP loss of $0.62 per share, versus analysts’ expected profit of $0.14. Although revenue exceeded estimates, the earnings miss and swing from a year-earlier profit create near-term concern. Some reports cite adjusted earnings of $0.61 per share, highlighting a difference in reporting methodology. PTC Therapeutics swings to Q3 loss

Analysts Set New Price Targets

A number of brokerages recently issued reports on PTCT. Royal Bank Of Canada increased their price objective on PTC Therapeutics from $75.00 to $77.00 and gave the stock a “sector perform” rating in a research report on Friday. Cantor Fitzgerald boosted their target price on PTC Therapeutics from $130.00 to $137.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 22nd. Wells Fargo & Company boosted their target price on PTC Therapeutics from $109.00 to $112.00 and gave the stock an “overweight” rating in a research report on Friday. Raymond James Financial set a $106.00 target price on PTC Therapeutics in a research note on Tuesday, October 20th. Finally, TD Cowen raised their price target on PTC Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, PTC Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $95.64.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company’s commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency.